Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 5, 2008, Pages 467-473

  Zhao, Gong ^a,c   Serpllion, Sabrina ^b   Shryock, John ^a   Messina, Eric ^b   Xu, Xiaobin ^b   Ochoa, Manuel ^b   Belardinelli, Luiz ^a   Hintze, Thomas H ^b  

^a CV THERAPEUTICS INC   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c NONE   (United States)

Author keywords

Conscious dogs; Heart rate; Pharmacologic stress testing; Regadenoson; The QT interval

Indexed keywords

ATROPINE NITRATE; HEXAMETHONIUM; MUSCARINIC RECEPTOR BLOCKING AGENT; PROPRANOLOL; REGADENOSON; SOTALOL; UNCLASSIFIED DRUG; ADENOSINE A2A RECEPTOR; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC GANGLION; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAPHY; EXPERIMENTAL DOG; HEART ATRIUM PACING; HEART MUSCLE PERFUSION; HEART RATE; IMAGING SYSTEM; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; ANIMAL; BLOOD PRESSURE; DOG; DRUG POTENTIATION; EXERCISE TEST; HEART SCINTISCANNING; METHODOLOGY;

ANIMALS; BLOOD PRESSURE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART RATE; MALE; MYOCARDIAL PERFUSION IMAGING; PURINES; PYRAZOLES; RECEPTOR, ADENOSINE A2A;

EID: 59449095471     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31818e035b     Document Type: Article

References (16)

1. 2A adenosine receptor agonists. Am J Cardiol. 2004;94(suppl):33D-42D.
2. 2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol. 2005;46:2069-2075.
3. Lieu H, Shryock JC, von-Mering GO, at al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 2007;14:514-520.
4. Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14:645-658.
5. 2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: Potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol. 2003;41: 132-139.
6. 2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther. 2003;307:182-189.
7. 2A receptor agonist. J Cardiovasc Pharmacol. 2007;49:369-375.
8. Gordi T, Blackburn B, Lieu H, Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol. 2007;47:825-833.
9. Ackerman MJ. Long QT syndrome. Pediat Rev. 1998;19:232-238.
10. th edition. New York, NY: McGraw-Hill; 2001:843-70.
11. Kassotis J, Sauberman RB, Cabo C, et al. Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction. J Cardiovasc Electrophysiol. 2003;14:1233-1244.
12. Thomsen MB, Verduyn SC, Stengl M, et al. Increased short-term variability of repolarization predicts d-sotalol-induced Torsades de Pointes in dogs. Circulation. 2004;110:2453-2459.
13. Batey AJ and Doe CPA. A method for QT correction based on beat-tobeat analysis of the QT/RR interval relationship in conscious telemetered beagle dogs. J Pharmacol Toxicol Methods. 2002;48:11-19.
14. Larroude CE, Jensen BT, Agner E, et al. Beat-to-beat QT dynamics in paroxysmal atrial fibrillation. Heart Rhythm. 2006;3:660-664.
15. Biaggioni I, Killian TJ, Mosqueda-Garcia R, et al. Adenosine increases sympathetic nerve traffic in humans. Circulation. 1991;83:1668-1675.
16. 2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316:695-702.